Ontology highlight
ABSTRACT:
SUBMITTER: Algazi AP
PROVIDER: S-EPMC3251861 | biostudies-literature | 2012 Jan
REPOSITORIES: biostudies-literature
Algazi A P AP Weber J S JS Andrews S C SC Urbas P P Munster P N PN DeConti R C RC Hwang J J Sondak V K VK Messina J L JL McCalmont T T Daud A I AI
British journal of cancer 20111129 1
<h4>Background</h4>Src inhibitors sensitise melanoma cells to chemotherapy in preclinical models. The combination of dasatinib and dacarbazine was tested in a phase I trial in melanoma.<h4>Methods</h4>Patients had ECOG performance status 0-2 and normal organ function. Dacarbazine was administered on day 1 and dasatinib on day 2 through 19 of each 21-day cycle. Both were escalated from 50 mg b.i.d. of dasatinib and 800 mg m(-2) of dacarbazine. Available pre-treatment biopsies were sequenced for B ...[more]